RAF1 and brain neoplasm: Moreover, next-generation sequencing (NGS) of tumor specimens has enabled identification of other mutations in the BRAF gene in primary brain tumors, but many of these do not respond to FDA-approved RAF inhibitors and may in fact progress more rapidly.